Viewing Study NCT02027961


Ignite Creation Date: 2025-12-24 @ 12:43 PM
Ignite Modification Date: 2026-02-21 @ 10:00 PM
Study NCT ID: NCT02027961
Status: COMPLETED
Last Update Posted: 2019-05-17
First Post: 2013-11-20
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
Sponsor: MedImmune LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic or Unresectable Melanoma, durvalumab (MEDI4736), dafrafenib, trametinib, BRAF-mutation positive, … View